Galapagos (Page 24 sur 26)

Bonjour

Comment bien interpréter les infos de ce site,
Sur les huit flèches, quelle sont les 3 ou 4 plus importantes à vos yeux qui peuvent déterminer si le titre mérite un investissement.
http://sadifanalytics.com/stock/GLPG/53132

Salut tout le monde,
sur KBC ce matin :

€ 55.00
RATING UNCHANGED
Source: Thomson Reuters Datastream
News:
Galapagos reported 1H15 financials which largely confirmed the anticipated trend of lower top-line and higher R&D costs. The cash position is very strong. The outlook for the full year remains unchanged.
Our View:
Galapagos reported a 1H15 top-line drop of 18% in line with our expectation € 37m (CSS € 34m). The drop relates to lower milestone payments from partners (€ 1.4m vs € 10m in 1H14) and revenues now largely exist of non-cash AbbVie upfront payment recognitions. Other income was stable at € 10m. R&D expenses strongly increased to € 63m (more than expected, KBCSs of € 58m, vs € 53m in 1H14). G&A and S&M increased to € 9m versus € 7.4m in 1H15. This resulted in an expected higher operating loss of -€ 36m (vs -€ 16m in 1H14). Adding a € 1.5m tax (recognition of deferred asset) the net loss widened to -€ 34m (vs -€ 15m in 1H14).
The strong cash position of € 404m is well in-line with expectations, following the successful capital increase linked to the NASDAQ listing and € 10m from exercised warrants. As expected, GLPG’s operational cash burn substantially increased in 1H15, reaching € 62m vs € 42m in 1H14. For the full year, the company reiterates it operational cash burn of € 110-130m. Regarding future cash on the balance sheet, Galapagos indicates to be eligible for € 36m of French tax receivables, payable in 4.5 yearly tranches, and € 22m in Belgian R&D tax incentives, payable as of 2016.
In its outlook for the remainder of the year, the company largely reiterates previously communicated timelines:
- filgotinib Darwin2 24 week data in rheumatoid arthritis are still expected this month (the Darwin1 24 week data confirmed last week the 12week data, and we expect Darwin2 24 week data to confirm as well), and AbbVie is to make licensing decision thereafter.
- A second cystic fibrosis (CF) corrector pre-clinical molecule will be nominated this quarter and top-line of the phase 1 study (in healthy subjects) with the potentiator is expected in 4Q15. The start of the CF potentiator phase 2 and the phase 1 of the first corrector are still expected before YE15.
- Phase 2 data of filgotinib in crohn's: in a separate press-release, Galapagos announced the phase 2 study (FITZROY) has recruited all patients (175 pts, 20 weeks treatment). The interim result at 10 weeks will be reported before YE15 while the final 20 week data will be reported in 1Q16. The first part has induction at 200mg versus placebo, the second part has induction at 100mg versus placebo and maintenance at 200 and 100 mg.
- Progress is expected in earlier stage R&D programs
Conclusion:
The 1H15 financial report conformed the expectation: the top-line came down due to lower alliance income, increasing R&D cost due to the maturing pipeline and one of the strongest cash positions in the European midcap biotech space. The outlook yields no surprises, nor in the financials, nor in the timelines of near-term news flows. We believe the next stock trigger is AbbVie's decision regarding filgotinib, whereby the market attributes a high probability that it will be inlicensed. Conference call at 2PM.

Je me taperais bien la tête au mur d'avoir largué à 19,55 €.

Bien à vous,
demat

@Praline

Tu vas rire, j'ai encore un ordre d'achat à 19,77 du temps ou elle traînait après avoir franchis les 21/22 euros, j'avais un espoir d'un retour sous les 20 euros.
Maintenant, vu la période, mois d'août, donc moins d'intervenant sur le marché, je tenterais un ordre opportuniste à un prix de 47,77 euros. Parfois sur une journée de bourse il y a excès à la baisse qui ce comble assez vite et donc c'est ceux qui ont un ordre rentré à l'avance qui ont l'avantage.  En semaine, rappelle toi la chute de Tigénix à 0,65 cent, une chute de 10% mais il fallait être devant son pc pour le voir ou avoir un ordre opportuniste qui traîne à 0,66 ou 0,65 cent. Si tu aimes une action n'hésite pas à rentrer un ordre dessus en mettant 7 à 10% moins cher que le cours, en France ceux qui avait un tel ordre sur crédit agricole ont été servis et sont maintenant en profit. C'est un peu le hasard mais il faut tenter je crois.

Bon résultat de DARWIN 2 sur 24 semaines.
AbbVie a 60 jours pour décider s'il prend on non une licence, si c'est le cas GLPG recevra 200 millions $.

Où s'arrêtera-t-elle ? 58,30 + 7,96% à 11:44. Tout le contraire de THR. Peut-on encore risquer d'y (ré)entrer ?
Dans la liste des valeurs à suivre ce matin :

August 18 (Reuters) - Securities analysts revised their ratings and price targets on several
European companies, including Bovis Homes and William Hill, on Tuesday.
         
  * Galapagos NV   : Jefferies ups target price to 73 euros from 47 euros; rating buy   

Si certains souhaitent voir la liste complète je peux la poster.

Bien à vous,
demat

Salut tout le monde,
voici un communiqué :

UPDATE 2-AbbVie scraps Galapagos deal to focus on own arthritis drug
15:32 (25/09) - Source: RTRS

(Adds details, analyst comment)
    By Amrutha Penumudi
    Sept 25 (Reuters) - AbbVie Inc  ABBV.N  said its
experimental drug improved symptoms of rheumatoid arthritis in
mid-stage studies and scrapped plans to buy rights to a similar
treatment from Belgium's Galapagos NV   . 
    Galapagos shares were down 27 percent at 40.20 euros in
Amsterdam. AbbVie shares rose 2 percent to $57.66 in early
trading on Friday.
    Analysts said the drug's success would help AbbVie save
about $1 billion that it would have otherwise paid Galapagos in
royalties for filgotinim.   
    "Galapagos management can negotiate another deal with a key
rheumatoid arthritis player and advance filgotinim quickly,"
Morgan Stanley analyst Matthew Harrison said in a note.
    Galapagos, with its promising arthritis drug candidate, has
been touted as a tempting takeover target for companies such as
AbbVie and Johnson & Johnson  JNJ.N .   
    During two mid-stage studies, patients taking the drug,
ABT-494, responded to the treatment at week 12, across all dose
levels except for the lowest dose in the second study, AbbVie
said.     
    The trials tested the drug in patients who were not
responding adequately to two commonly prescribed arthritis
treatments, TNF inhibitors and methotrexate.
    "ABT-494 also offers a faster path to Phase 3 development
with less uncertainty," Chief Scientific Officer Michael
Severino said in a statement on Friday.
   Rheumatoid arthritis occurs when the immune system attacks
the body's tissues, causing joint pain, swelling and stiffness.
    ABT-494 belongs to class of drugs known as JAK1 inhibitors
that block the action of enzymes responsible for the
inflammatory process of rheumatoid arthritis.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil
D'Silva)
((penumudi.amrutha@thomsonreuters.com; within U.S. +1 646 223
8780 outside U.S. +91 80 6749 4486; Reuters Messaging:
penumudi.amrutha.thomsonreuters.com@reuters.net))

Keywords: ABBVIE STUDY/

Un autre avis de Cédric Boite

http://www.accioz.be/index.php/blog/726 … -galapagos